Results 131 to 140 of about 109,902 (263)

Synthesis and characterization of bevacizumab-functionalized nanoliposomes loaded with regorafenib and fluorescent carbon dots for triple-negative breast cancer theranostics. [PDF]

RSC Adv
Aryanmanesh A, Abbasi Kajani A.
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Inhibition of Pellino-1 reverts the progression and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Cell Death Dis
Zhou Q, Xu G, Li Z, Xu Y, Guan J, Li Z, Li M, Zu T, Li Y, Lu C, Ji C, Zhao B.   +11 more
europepmc   +1 more source

Protein Corona‐Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia

Allergy, EarlyView.
Cuishuang Dong, Xu Zhang, Haoyue Wang, Jiajing Cui, Shuai Han, Yibo Wang, Huanying Zhao, Yang Song, Yuan Zhang, Xiaobo Li   +9 more
wiley   +1 more source

Targeting the NR3C1‐ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer

Cancer Science, EarlyView.
The glucocorticoid receptor NR3C1 drives prostate cancer radioresistance by upregulating ACSL4. High ACSL4 levels create a lipid metabolic vulnerability. The clinical agent DHA synergizes with ACSL4 to induce lipid peroxidation and ferroptosis, effectively overcoming radioresistance.
Jing Yang, Puyuan Chen, Yawen Zheng, Feiyue Shi, Min Wang, Luwei Xu, Xiaowei Wei, Xiumei Wang   +7 more
wiley   +1 more source

Real-world treatment patterns in patients with biochemical recurrence after local prostate cancer therapy. [PDF]

Future Oncol
McKay RR, Khan N, Shore ND, Chen G, Hlebec V, Srinivasan S, Spratt DE.   +6 more
europepmc   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

Cancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang, Changyi Fan, Shiheng Chen, Tianyue Lu, Yuanyuan Li, Feng Du, Shanshan Wang   +6 more
wiley   +1 more source

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. [PDF]

Hemasphere
Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.   +35 more
europepmc   +1 more source

CANRIG: Cross‐Attention Neural Face Rigging with Variable Local Control

Computer Graphics Forum, EarlyView.
Abstract Facial animation is one of the most labor‐intensive aspects of animation and VFX, as traditional rigging consumes weeks of expert time and forces animators to spend countless hours manipulating hundreds of controls to achieve varied expressions.
Arad Mohammadi, Sebastian Weiss, Jakob Buhmann, Loic Ciccone, Robert W. Sumner, Derek Bradley, Martin Guay   +6 more
wiley   +1 more source

Analytical performance evaluation and method comparison of the 1copy BCR::ABL1 qPCR assay for monitoring chronic myeloid leukemia. [PDF]

Pract Lab Med
Kim H, Kim DY, Kim H.
europepmc   +1 more source